ABSTRACT

The Objective of study is “Dementia is also a symptom of a variety of specific structural brain diseases as well as several system degenerations. Dementia is 7th leading cause of death globally.50 million people lives with dementia. A new case of dementia diagnosed every 3 seconds. Dementia shows huge economic impact. Dementia targets person’s life. Alzheimer’s disease (AD) accounts for nearly 50% of all cases of dementia. It affects about 6% of the population aged over the 65 and increases the incidence with age .Alzheimer’s disease (AD) is a neurodegenerative disorder that destroys cells in the brain associated with loss of neurons in distinct brain areas. Currently, various Nootropic drugs are available in the market for treating AD as well as dementia like physostigmine, rivastigmine, piracetam, donepezil, galantamine and tacrine. These drugs are effective but they are associated with side effects like excitement, convulsions, and tremors and are required to be used cautiously in peptic ulcer, asthmatic and hypotensive patients. Hence, there is need of a drug which is effective for neuroprotection, learning and memory enhancement; Hence in present investigation, an attempt will be made to evaluate beneficial effect of a phytoconstituent on Nootropic activity. Keywords: Vanillic acid (VA), Dementia, Nootropic activity, Alzheimer’s disease (AD)
Publication date: 01/04/2022

https://ijbpas.com/pdf/2022/April/MS_IJBPAS_2022_6049.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2022/11.4.6049